Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4.

Shaker O, El-Shehaby A, Fayez S, Zahra A, Marzouk S, El Raziky M.

Cell Biochem Funct. 2013 Oct;31(7):620-5. doi: 10.1002/cbf.2954. Epub 2013 Feb 11.

PMID:
23400862
2.
3.
4.

Myxovirus resistance, osteopontin and suppressor of cytokine signaling 3 polymorphisms predict hepatitis C virus therapy response in an admixed patient population: comparison with IL28B.

Angelo AL, Cavalcante LN, Abe-Sandes K, Machado TB, Lemaire DC, Malta F, Pinho JR, Lyra LG, Lyra AC.

Clinics (Sao Paulo). 2013 Oct;68(10):1325-32. doi: 10.6061/clinics/2013(10)06.

5.

Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.

Naga M, Amin M, Algendy D, Elbadry A, Fawzi M, Foda A, Esmat S, Sabry D, Rashed L, Gabal S, Kamal M.

World J Gastroenterol. 2015 Oct 21;21(39):11141-51. doi: 10.3748/wjg.v21.i39.11141.

6.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

7.

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.

El Awady MK, Anany MA, Esmat G, Zayed N, Tabll AA, Helmy A, El Zayady AR, Abdalla MS, Sharada HM, El Raziky M, El Akel W, Abdalla S, Bader El Din NG.

J Gastroenterol Hepatol. 2011 May;26(5):843-50. doi: 10.1111/j.1440-1746.2010.06605.x.

PMID:
21182542
8.

SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.

Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, Egashira T, Hashimoto M, Mishiro S, Mochida S, Fujiwara K.

J Gastroenterol. 2005 Apr;40(4):381-8.

PMID:
15868370
9.

Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.

Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H.

J Med Virol. 2012 Mar;84(3):438-44. doi: 10.1002/jmv.23207.

PMID:
22246829
10.

Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients.

Sadik NA, Shaker OG, Ghanem HZ, Hassan HA, Abdel-Hamid AH.

Arch Virol. 2015 Sep;160(9):2181-95. doi: 10.1007/s00705-015-2493-0. Epub 2015 Jun 23.

PMID:
26095186
11.

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.

Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Iio S, Oshita M, Hagiwara H, Mita E, Inui Y, Hijioka T, Inada M, Tamura S, Yoshihara H, Inoue A, Imai Y, Miyagi T, Yoshida Y, Tatsumi T, Kanto T, Kasahara A, Hayashi N, Takehara T.

J Gastroenterol. 2014 Apr;49(4):737-47. doi: 10.1007/s00535-013-0824-z. Epub 2013 May 21.

PMID:
23689988
12.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.

Hepatology. 2012 Feb;55(2):336-42. doi: 10.1002/hep.24683. Epub 2012 Jan 3.

PMID:
21932415
13.

Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.

Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y.

J Med Virol. 2013 Jul;85(7):1180-90. doi: 10.1002/jmv.23597.

PMID:
23918536
14.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

15.

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.

Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.

J Hepatol. 2012 Sep;57(3):534-40. doi: 10.1016/j.jhep.2012.04.027. Epub 2012 May 18.

PMID:
22613000
16.

Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4.

Rizk NM, Derbala MF.

Clin Res Hepatol Gastroenterol. 2013 Jun;37(3):262-8. doi: 10.1016/j.clinre.2012.09.012. Epub 2012 Nov 6.

PMID:
23137758
17.

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S.

J Gastroenterol. 2012 Sep;47(9):1014-21. doi: 10.1007/s00535-012-0560-9. Epub 2012 Mar 2.

PMID:
22382633
18.

Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C.

Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S, Ceriani E, Fornasiere E, Pasino M, Ieluzzi D, Pirisi M, Toniutto P.

Hepatology. 2012 Nov;56(5):1641-50. doi: 10.1002/hep.25848. Epub 2012 Oct 14.

PMID:
22610885
19.

Predictive potential of IL-18 -607 and osteopontin -442 polymorphism in interferon-based therapy of HCV infection in the Pakistani population.

Imran M, Manzoor S, Parvaiz F.

Viral Immunol. 2014 Oct;27(8):404-11. doi: 10.1089/vim.2014.0044. Epub 2014 Sep 8.

PMID:
25198668
20.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

Supplemental Content

Support Center